QIAGEN Clinical Insight (QCI™) Interpret for Oncology
Enabling precision medicine in oncology through accurate and scalable NGS variant interpretation and reporting with QIAGEN Clinical Insight (QCI™)
Next-generation sequencing (NGS) tests are increasingly being adopted in clinical labs, but there are significant challenges in accurately classifying variants based on levels of evidence and offering actionable insights for healthcare professionals. In this showcase, Dr. Helen Fernandes (Weill Cornell Medicine) and Dr. Andrea Gonzales (Virginia Commonwealth University) will highlight some of the challenges that clinical testing labs encounter implementing NGS tests and review their concordance study results using the clinical decision support platform, QIAGEN Clinical Insight (QCI). They will describe how QCI helps them to scale their testing services and improves the actionability of reporting through a comprehensive evidence-based approach and CLIA-CAP compliant reporting guidelines.